Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy

Diabetes

Volumn 40, Issue 1, 1991, Pages 129-133

  Florkowski, Christopher M ^b   Rowe, Bethan R ^b   Nightingale, Simon ^b   Harvey, Timothy C ^b   Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PONALRESTAT;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; COMPARATIVE STUDY; DIABETIC NEUROPATHIES; HUMAN; MEDIAN NERVE; MIDDLE AGE; NEURONS, AFFERENT; PHTHALAZINES; SENSORY THRESHOLDS; SUPPORT, NON-U.S. GOV'T; TIBIAL NERVE;

EID: 0026017232     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.40.1.129     Document Type: Article

References (22)

1. Ward JD, Baker RWR, Davis BH: Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue. Diabetes 21:1173-78, 1972
2. Mayer JH, Tomlinson DR: Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 25:433-38, 1983
3. Jaspan J, Maselli R, Herold K, Bartkus C: Treatment of severely painful diabetic neuropathy with an aldose reduclase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 2:758-62, 1983
4. Judzewitsch RG, Jaspan JB, Polansky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vikadinovic C, Bernstein L, Schneider M, Liang K-Y, Gabbay KH, Rubenstein AM, Porte D Jr: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 308:119-25, 1983
5. Lewin IG, O'Brien IAD, Morgan MH, Corrall RJM: Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil in symptomatic diabetic neuropathy. Diabetologia 26:445-48, 1984
6. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IAD, Corral RJM: Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabetic Med 5:537-42, 1988
7. Young RJ, Ewing DJ, Clarke BF: A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32:938-42, 1983
8. Gabbay KH, Spack L, Loo S, Hirsch HJ, Ackil AA; Aldose reductase inhibition: studies with alrestatin. Metabolism 28:471-76, 1979
9. Handelsman DJ, Turtle JR: Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30:459-64, 1981
10. Young RJ, Matthews DM, Clarke BF, Martyn CN, Ewing DJ: Aldose reductase inhibition for diabetic neuropathy (Letter). Lancet 2:969, 1983
11. Goto Y: Clinical study of a new aldose reductase inhibitor (ONO-2235) in diabetic neuropathy. Jpn Diabetic Soc 28:89-99, 1985
12. Boulton AJM, Tolrestat in Neuropathy Study Group: The efficacy and safety of Tolrestat, a new aldose reductase inhibitor, in symptomatic diabetic neuropathy: report of a one year multi-center trial (Abstract). Diabetic Med 3:568A, 1986
13. Engerman RL, Kramer JW: Dogs with induced or spontaneous diabetes as models for the study of human diabetes mellitus. Diabetes 31 (Suppl. 1):26-29, 1982
14. Sima AAF, Thibert P: Proximal motor neuropathy in the BB-Wistar rat. Diabetes 31:784-88, 1982
15. Sima AAF: Neuropathic and ocular complications in the BB-Wistar rat. In Lessons From Animal Diabetes. Shafrir E, Renold AE, Eds. London, Libbey, 1984, p. 447-56
16. Williams E, Timperley WR, Ward JD, Duckworth T: Electron microscopic studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 33:462-70, 1980
17. Dyck PJ, Knornes JL, O'Brien P, Okazaki H, Lais A, Englestad J: The spatial distribution of fiber loss in diabetic polyneuropathy suggests Ischaemia. Ann Neurol 19:444-49, 1986
18. Chakrabarti S, Sima AAF, Nakajima T, Yagihashi S, Greene DA: Aldose reductase in the BB-rat: isolation, immunological identification and localisation in the retina and peripheral nerve. Diabetologia 30:244-51, 1987
19. Mulvany MJ: Vascular effects of altered sodium potassium pump activity. Scand J Clin Lab Invest 46:40-48, 1986
20. Robison WG Jr, Kador PF, Akagi Y, Kinoshita JH, Gonzalez R, Dvornik D: Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes 35:295-99, 1986
21. Sima AAF, Bril V, Nathaniel V, McEwan TAJ, Brown MB, Lattimer SA, Greene DA: Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319:542-48, 1988
22. Norris SC, Bastain W, Mirrlees DJ, Yates RA, Wardleworth AG: Effect of an aldose reductase inhibitor IC1128,436 on erythrocyte aldose reductase in volunteers (Abstract). Diabetic Med 1:166A, 1984